Skip to main content
SpringerLink
Log in

Tolvaptan

Lack of efficacy during treatment of autosomal dominant polycystic kidney disease: case report

Reactions Weekly Aims and scope

Cite this article

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Munoz JM, et al. LONG-TERM SAFETY OF TREATMENT WITH TOLVAPTAN IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. Nephrology Dialysis Transplantation 37 (Suppl. 3): i15 abstr. MO031, May 2022. Available from: URL: http://doi.org/10.1093/ndt/gfac062.012 [abstract]

Download references

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tolvaptan. Reactions Weekly 1914, 410 (2022). https://doi.org/10.1007/s40278-022-18996-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-18996-1

search

Navigation